Pricing Log in Create free account
Wednesday 4 November 2026 Export ASMB’s income statement to Excel — free account

Assembly Biosciences, Inc.

ASMB Healthcare Biotechnology

Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024.

Revenue
+38.9%
EPS
+85.0%
Free cash flow
+7.58%

Quarter to June 2026, against a year earlier

19.80 0.12 −0.60%
Market cap
$405.6M
P/E
0.0×
Fwd P/E
−173×
Dividend yield
—
F-score
4/9
Altman Z
1.06
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.25
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 2 — — 1 — — — — 4
Insider Ownership 32.11%

Capital & Financial Ratios $m

Size
Market Cap 405.59
Revenue ttm 74.85
Net income ttm (0.04)
Free cash flow ttm (38.57)
Net debt Q (320.36)
Valuation
P/E 0.00
Forward P/E (173.00) (negative: loss-making)
Price / sales 5.04
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.23
Financial health
Current ratio Q 13.99 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 2.55
Growth
Revenue growth Q +38.94% (above 0%: growing)
Operating income growth Q +42.81% (above 0%: growing)
EPS, this year −10.58% (below 0%: weak)
EPS, next year A −401.32% (below 0%: weak)
Revenue, next year A −12.27% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +44.88% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.8×, against a ten-year median of 0.5×; over the ten years it ranged from −1.2× in 2024 to 98.3× in 2018.
P/S against its own 10 years 53.96%
10-year low 10-year high
P/B against its own 10 years 36.26%
10-year low 10-year high
EV/Sales against its own 10 years 8.13%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 130 112 248 320
Receivables 0 — 1 1
Inventory — — — —
Other — — — —
134 116 255 328
2023 2024 2025 Q'26
Payables 0 1 1 1
ST’ Debt — — — —
Other — — — —
39 48 49 23

Compound Annual Growth %

10y 5y 3y
Sales — 35.27% 126.12%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 5.70% (2.99%) 35.74%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.70 Actual −0.20

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.50 −0.72 Miss by 0.22
Q4 FY25 −0.51 2.48 Beat by 2.99
Q1 FY26 −0.73 −0.54 Beat by 0.19
Q2 FY26 −0.70 −0.20 Beat by 0.50
Q3 FY26 −0.44 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.54) (0.20) — — —
’25 (1.17) (1.33) (0.72) 1.30 (0.55)
’24 (1.66) (1.98) (1.51) (1.57) (6.69)
’23 (4.44) (3.84) (3.24) (2.06) (13.38)
’22 (5.76) (6.12) (5.76) (5.52) (23.05)
’21 (8.28) (6.60) (4.92) (16.45) (36.01)
’20 (9.12) 2.28 (1.08) (13.32) (21.01)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 8 13 — — —
’25 9 10 11 42 72
’24 6 9 7 7 29
’23 — — — — 7
’21 — — 6 — 6
’20 4 39 35 1 79
’19 4 3 4 5 16
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (15) — — —
’25 (23) (17) (15) 14 (41)
’24 (18) (17) (15) 0 (51)
’23 (23) (14) (14) 74 23
’22 (28) (18) (20) (19) (84)
’21 (33) (22) (19) (19) (93)
’20 (25) (23) 11 (25) (63)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (15) — — —
’25 (23) (17) (15) 14 (41)
’24 (18) (17) (15) 0 (51)
’23 (23) (14) (14) 74 23
’22 (28) (18) (20) (19) (85)
’21 (36) (22) (19) (19) (96)
’20 (25) (24) 11 (25) (63)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 9 15 16 79 6 — 7 29 72 75 +29.7% 63 34 49 (12.3%)
Gross margin, % 0.00 100.00 100.00 100.00 100.00 100.00 0.00 100.00 100.00 100.00 100.00 +100.0 pt
EBT (45) (52) (90) (98) (62) (132) (93) (61) (40) (6) 0 (19.9%)
EBT margin, % 0.00 (575.00) (605.59) (616.48) (78.57) (2,116.82) 0.00 (854.32) (139.72) (8.47) (0.06) (8.5) pt
Net income (44) (43) (91) (98) (62) (130) (93) (61) (40) (6) 0 (19.7%)
Per share, $
Per share, $ Revenue 0.00 6.10 7.79 7.30 26.81 1.73 0.00 1.57 4.75 6.45 3.97 n/m
Earnings (30.85) (28.93) (47.78) (44.66) (21.01) (36.01) (23.05) (13.38) (6.69) (0.55) (0.16) (36.1%)
Cash flow (24.31) 1.26 (34.20) (38.43) (21.33) (25.91) (20.94) 4.97 (8.51) (3.67) (2.04) (19.0%)
Capex (0.10) (0.58) (0.18) (0.71) (0.16) (0.62) (0.03) (0.05) 0.00 (0.01) 0.00 (27.2%)
Free cash flow (24.41) 0.67 (34.38) (39.14) (21.49) (26.53) (20.96) 4.92 (8.52) (3.67) (2.05) (19.0%)
Book value 55.67 76.50 110.91 124.90 81.52 46.86 20.49 8.98 5.56 18.44 16.21 (11.6%)
Shares, m 1 1 2 2 3 4 4 5 6 11 16 +25.7%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 0.0
P/S — 91.05 34.83 33.64 2.71 1.24 — 0.56 3.32 7.99 5.04 21.9
P/B — 7.26 2.45 1.97 0.89 0.60 — 1.11 2.84 2.80 1.23 2.5
EV/Sales — 77.75 20.10 16.48 (0.03) (0.56) — (1.04) (0.61) 4.56 0.76 14.6
EV/FCF — 824.79 (4.56) (3.07) 0.03 0.48 — (3.76) 0.34 (8.02) (1.47) 100.8
Cash, $m
Cash, $m Operating cash flow (35) 2 (65) (84) (63) (93) (84) 23 (51) (41) (38) +1.8%
Capex 0 (1) 0 (2) 0 (2) 0 0 0 0 0 (8.5%)
Free cash flow (35) 1 (65) (86) (63) (96) (85) 23 (51) (41) (39) +1.8%
Balance, $m
Balance, $m Working capital 46 110 204 258 200 138 81 95 68 206 305 +18.0%
Net debt (53) (120) (218) (274) (216) (147) (92) (130) (112) (248) (320) +18.7%
Shareholders’ equity 80 113 211 273 241 169 83 41 33 207 306 +11.1%
Returns, %
Returns, % ROA (38.18) (32.02) (41.50) (32.12) (19.95) (54.75) (63.58) (51.32) (31.39) (3.25) (0.02) +34.9 pt
ROIC (105.14) 0.00 0.00 0.00 (167.54) (371.85) 0.00 0.00 0.00 0.00 0.00 +105.1 pt
ROE (44.57) (44.36) (56.06) (40.36) (24.19) (63.42) (74.00) (98.95) (107.92) (5.10) (0.03) +39.5 pt
People
People Employees 69 79 95 115 139 102 68 65 73 73 — +0.6%
Revenue/emp, $m 0.00 0.11 0.16 0.14 0.57 0.06 0.00 0.11 0.39 0.99 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Assembly Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RLMD Relmada Therapeutics, Inc. $455.5M — (loss-making) — — n/m −50.06% (below 0%: shrinking) 0.00% 0.00% Compare
ASMB Assembly Biosciences, Inc. $405.6M — (loss-making) — (loss-making) +38.94% (above 0%: growing) n/m +7.58% (above 0%: growing) 100.00% (47.44%)
EDIT Editas Medicine, Inc. $399.3M — (loss-making) — (loss-making) +232.31% (above 0%: growing) n/m +40.72% (above 0%: growing) 100.00% (156.05%) Compare
ALT Altimmune, Inc. $396.8M — (loss-making) — (loss-making) +520.00% (above 0%: growing) n/m −25.27% (below 0%: shrinking) 100.00% 0.00% Compare
CCCC C4 Therapeutics, Inc. $394.9M — (loss-making) — (loss-making) +2.75% (above 0%: growing) n/m +86.84% (above 0%: growing) 100.00% (397.88%) Compare
BLSM BlossomHill Therapeutics, Inc. $394.5M — (loss-making) — — n/m — — 0.00% Compare
AVTX Avalo Therapeutics, Inc. $388.8M — (loss-making) — (loss-making) −70.14% (below 0%: shrinking) n/m +75.70% (above 0%: growing) 55.73% 0.00% Compare
ZURA Zura Bio Limited $384.3M — (loss-making) — — n/m −26.22% (below 0%: shrinking) — 0.00% Compare
AUTL Autolus Therapeutics PLC Sponsored ADR $376.6M — (loss-making) — (loss-making) +118.37% (above 0%: growing) n/m +67.55% (above 0%: growing) 55.20% (95.95%) Compare
Median of peers $394.7M — — +118.37% — +40.72% 77.87% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 22 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.48m 5.51m 218.01
2024 1.77m 2.15m 101.15
2023 1.37m 1.13m 63.08

Ownership

Directors and executive officers, together 3.50%
Gilead Sciences, Inc. 28.30%
Entities affiliated with Commodore Capital L.P. 9.80%
Entities affiliated with RA Capital Management L.P. 9.30%
Entities affiliated with Janus Henderson Group plc 8.40%
Entities affiliated with Farallon Capital Partners L.P. 7.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Assembly Biosciences, Inc. (ASMB) Latest News

29 Oct

Impact 4 · · GlobeNewswire
Impact 4 · · Insider Monkey

5 Oct

Impact 3 · · GlobeNewswire

8 Sep

Impact 4 ·

13 Aug

Impact 3 ·

8 Jun

Impact 4 · · MarketBeat

5 Jun

Impact 4 · · MarketBeat

22 May

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswire

14 May

Impact 3 · · MarketBeat

13 May

Impact 4 · · Simply Wall St.
Impact 3 · · GlobeNewswire

7 May

Impact 3 · · GlobeNewswire

9 Apr

Impact 4 · · GlobeNewswire

19 Mar

Impact 4 ·
Impact 3 ·
Impact 3 · · Associated Press Finance

24 Dec

Impact 4 · · Simply Wall St.

23 Dec

Impact 4 · · Zacks

22 Dec

Impact 4 · · Business WireMT NewswiresZacksInsider MonkeyMT NewswiresMT NewswiresMT NewswiresSimply Wall St.

8 Dec

Impact 4 · · GlobeNewswire

3 Dec

Impact 4 · · Simply Wall St.Associated Press FinanceSimply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

13 Nov

Impact 3 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

10 Nov

Impact 4 · · GlobeNewswire
Impact 3 ·

7 Nov

Impact 4 · · GlobeNewswireInsider MonkeyGuruFocus.comClinical Trials ArenaClinical Trials ArenaMT NewswiresMT NewswiresClinical Trials Arena

10 Oct

Impact 4 ·

22 Sep

Impact 4 ·
Impact 3 ·

11 Aug

Impact 4 · · clinicaltrialsarena.com
stockrow.com/ASMB · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com